Economic evaluation of endocrine therapy in the treatment of breast cancer

Anti-Cancer Drugs

Volumn 9, Issue 10, 1998, Pages 849-857

  Wait, Suzanne H ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Breast cancer; Economic analysis; Endocrine therapy; Quality of life

Indexed keywords

ARTICLE; BREAST CANCER; BUDGET; CANCER ADJUVANT THERAPY; ECONOMIC EVALUATION; HORMONAL THERAPY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0032438854     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199811000-00004     Document Type: Article

References (35)

1. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer 1996; 32A: 576-88.
2. Cancer Research Campaign. Incidence - UK Fact Sheet II 1992.
3. Rubens RD. Key issues in the treatment of advanced breast cancer. Expectations and outcomes. Pharmacoeconomics 1996; 9 (suppl 2): 1-7.
4. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-7.
5. Goldhirsch A, Wood WC, Ssenn HJ, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1995; 87; 1441-5.
6. NIH Consensus Conference. Treatment of early-stage breast cancer. J Am Med Ass 1991; 265: 391-5.
7. Bajetta E, Zilembo N, Di Leo Q, et al. Hormone therapy in advanced breast carcinoma: present and future needs. Cancer Treat Rev 1994; 20: 241-58.
8. Corry JF, Lonning PE. Systemic therapy for breast cancer: efficacy and cost-utility. Pharmacoeconomics 1994; 5: 198-212.
9. Chlebowski RT, Butler J, Nelson A, Lillington L. Breast cancer chemoprevention. Tamoxifen: current issues and future prospective. Cancer 1993; 72 (3 suppl): 1032-7.
10. Kennedy MJ. Systemic adjuvant theapy for breast cancer. Curr Opin Oncol 1994; 6: 570-7.
11. Mäenpää JU, Sirkka-Liisa A-F. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Aging 1997; 11: 261-70.
12. Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23 (4, Suppl 9): 10-20.
13. Perrone F, de Placido S, Gallo C, Carlomagno C, Lauria R, Bianco AR. Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? (review). Int J Oncol 1995; 7: 1129-37.
14. Wait S. The cost-effectiveness of breast cancer screening in France: from research to policy. In: Calvo F, Crepin M, Magdelenat H, eds. Breast cancer advances in biology and therapeutics (21st Meeting of the International Association for Breast Cancer Research). Paris: John Libbey Eurotext 1996.
15. Quality of life in breast cancer adjuvant therapy: validation and pilot testing of a combination of questionnaires. The Breast 1997; 6: 97-107.
16. Nayfield SG, Ganz PA, Moinpour CM, Cella DF, Hailey BJ. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Quality of Life Res 1992; 1: 203-10.
17. Hürny C, Bernhard J, Coates AS, et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 1996; 347: 1279-84.
18. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Int Med 1991; 114: 621-8.
19. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996.
20. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates A. Cost and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
21. Ludwig Breast Cancer Study Group. Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984; i: 1256-60.
22. De Haes JCJM, Van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-8.
23. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
24. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9.
25. Hill JE, Sutherland HJ, Meslin EM. Is there a role for preference assessments in research on quality of life in oncology? Quality of Life Res 1992; 1: 31-40.
26. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993; 11: 771-6.
27. Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Br Cancer Res Treat 1993; 25: 97-105.
28. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9 (suppl 2): 8-22.
29. Epstein RJ. Does the breast cancer dollar make sense? Eur J Cancer 1992; 28: 486-91.
30. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15; 71-85.
31. Richards MA, Braysher S, Gregory WM, Rubens RD. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67: 856-60.
32. Hurley SF, Huggins RM, Snyder RD, et al. The cost of breast cancer recurrences. Br J Cancer 1992; 65: 445-9.
33. de Koning HJ, van Ineveld BM, de Haes JC, et al. Advanced breast cancer and its prevention by screening. Br J Cancer 1992; 65: 950-5.
34. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Br Cancer Res Treat 1993; 25: 113-9.
35. Dess EC, Davidson NE. Management of early stage breast cancer: interventions and their effectiveness. Dis Manage Health Outcomes 1997; 2: 270-80.